IBI-343
- Generic Name
- IBI-343
IBI343 Combined with Chemotherapy in Advanced Pancreatic Cancer
Phase 2
Not yet recruiting
- Conditions
- Advanced Pancreatic Cancers
- Interventions
- Drug: Gemcitabine+Albumin-bound paclitaxel
- First Posted Date
- 2025-01-13
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 64
- Registration Number
- NCT06770439
- Locations
- 🇨🇳
First Affiliated Hospital of Zhejiang University Schlool of Medicine, Hangzhou, Zhejiang, China
A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 3
- Conditions
- Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT06238843
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Phase 1
Recruiting
- Conditions
- Locally Advanced Unresectable or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 470
- Registration Number
- NCT05458219
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Sun Yat-sen Memorial Hospital Sun Yat-Sen university, Guangzhou, Guangzhou, China
🇨🇳The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangzhou, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath